KCI requests Developmental Funds in support of: 1) recruitment of new basic and translational investigators;2) innovative projects that bridge several areas of research;and 3) development of Shared Resources (Cores). KCI's Developmental Funds have been used with endorsement of the External Advisory Board and the Senior Leadership of the Cancer Center to enhance the strengths of the current scientific Programs and to increase utilization of the Shared Resources. The Developmental Funds are critical to leverage the support of key Wayne State University stakeholders and local philanthropists. KCI's use of Developmental Funds to support faculty recruitment links with our plan for scientific research investment and supports our continued efforts to grow translational research by increasing interactions among basic scientists and clinicians. The Institute will continue its successful Strategic Research Initiative Grant program and its new Joint Post-Doctoral Training program in order to stimulate projects that have a high potential to go on to program project or SPORE applications. Two new developing Cores are proposed in this application for support from Developmental Funds. The proposed Clinical Imaging Researcii Core promotes imaging in support of cancer detection and therapy and facilitates the integration of functional imaging into routine clinical practice. Finally, the proposed Translational Research Core offers services to develop biochemical, molecular, or cellular assays tailored and validated according to the specific and customized translational research question associated with clinical trials.
Developmental Funds provide support to KCI to: 1) recruit new basic and translational investigators;2) support innovative projects that bridge several areas of research;and 3) support developing Shared Resources (Cores).
|Hamel, Lauren M; Penner, Louis A; Albrecht, Terrance L et al. (2016) Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer. Cancer Control 23:327-337|
|Xie, Yuran; Kim, Na Hyung; Nadithe, Venkatareddy et al. (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120-9|
|Cheriyan, Vino T; Muthu, Magesh; Patel, Ketan et al. (2016) CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. Oncotarget :|
|Moorman, Patricia G; Alberg, Anthony J; Bandera, Elisa V et al. (2016) Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol 26:654-62|
|Najor, Nicole A; Weatherford, Layne; Brush, George S (2016) Prevention of DNA Rereplication Through a Meiotic Recombination Checkpoint Response. G3 (Bethesda) 6:3869-3881|
|Herroon, Mackenzie Katheryn; Diedrich, Jonathan Driscoll; Podgorski, Izabela (2016) New 3D-Culture Approaches to Study Interactions of Bone Marrow Adipocytes with Metastatic Prostate Cancer Cells. Front Endocrinol (Lausanne) 7:84|
|Gimotty, Phyllis A; Shore, Ronald; Lozon, Nancy L et al. (2016) Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications. J Invest Dermatol 136:2168-2172|
|Ekanger, Levi A; Polin, Lisa A; Shen, Yimin et al. (2016) Evaluation of Eu(II) -based positive contrast enhancement after intravenous, intraperitoneal, and subcutaneous injections. Contrast Media Mol Imaging 11:299-303|
|Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :|
|Katz, Matthew H G; Shi, Qian; Ahmad, Syed A et al. (2016) Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 151:e161137|
Showing the most recent 10 out of 634 publications